Uro-A was able to downregulate prostate specific antigen (PSA) expression [37], a biomarker of prostate tumours that is also involved in tumour growth, invasion, and metastasis [84], and the expression and nuclear localisation of ARs. Here, KLK3 is linked to prostate neoplasm.